CA2859412C - Delivery of therapeutic agents using bacterial collagen-binding polypeptide segments - Google Patents

Delivery of therapeutic agents using bacterial collagen-binding polypeptide segments Download PDF

Info

Publication number
CA2859412C
CA2859412C CA2859412A CA2859412A CA2859412C CA 2859412 C CA2859412 C CA 2859412C CA 2859412 A CA2859412 A CA 2859412A CA 2859412 A CA2859412 A CA 2859412A CA 2859412 C CA2859412 C CA 2859412C
Authority
CA
Canada
Prior art keywords
collagen
cbd
pth
pog
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2859412A
Other languages
English (en)
French (fr)
Other versions
CA2859412A1 (en
Inventor
Joshua Sakon
Sagaya Theresa Leena Philominathan
Ranjitha KATIKANENI
Osamu Matsushita
Tulasi Ponnapakkam
Takaki Koide
Robert C. Gensure
Nozomu Nishi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kitasato University
Kagawa University
Montefiore Medical Center
University of Arkansas at Little Rock
Original Assignee
Kitasato University
Kagawa University
Montefiore Medical Center
University of Arkansas at Little Rock
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kitasato University, Kagawa University, Montefiore Medical Center, University of Arkansas at Little Rock filed Critical Kitasato University
Priority to CA3113972A priority Critical patent/CA3113972C/en
Publication of CA2859412A1 publication Critical patent/CA2859412A1/en
Application granted granted Critical
Publication of CA2859412C publication Critical patent/CA2859412C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A61Q7/02—Preparations for inhibiting or slowing hair growth
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24003—Microbial collagenase (3.4.24.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/57—Compounds covalently linked to a(n inert) carrier molecule, e.g. conjugates, pro-fragrances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Birds (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
CA2859412A 2011-12-14 2012-12-14 Delivery of therapeutic agents using bacterial collagen-binding polypeptide segments Active CA2859412C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3113972A CA3113972C (en) 2011-12-14 2012-12-14 Delivery of therapeutic agents using bacterial collagen-binding polypeptide segments

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161570620P 2011-12-14 2011-12-14
US61/570,620 2011-12-14
US201261596869P 2012-02-09 2012-02-09
US61/596,869 2012-02-09
PCT/US2012/069831 WO2013090770A2 (en) 2011-12-14 2012-12-14 Delivery of therapeutic agents by a collagen binding protein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3113972A Division CA3113972C (en) 2011-12-14 2012-12-14 Delivery of therapeutic agents using bacterial collagen-binding polypeptide segments

Publications (2)

Publication Number Publication Date
CA2859412A1 CA2859412A1 (en) 2013-06-20
CA2859412C true CA2859412C (en) 2021-05-25

Family

ID=48613370

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2859412A Active CA2859412C (en) 2011-12-14 2012-12-14 Delivery of therapeutic agents using bacterial collagen-binding polypeptide segments
CA3113972A Active CA3113972C (en) 2011-12-14 2012-12-14 Delivery of therapeutic agents using bacterial collagen-binding polypeptide segments

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3113972A Active CA3113972C (en) 2011-12-14 2012-12-14 Delivery of therapeutic agents using bacterial collagen-binding polypeptide segments

Country Status (7)

Country Link
US (3) US9579273B2 (enExample)
EP (4) EP3808365B1 (enExample)
JP (5) JP6366507B2 (enExample)
CA (2) CA2859412C (enExample)
DK (2) DK3391899T3 (enExample)
ES (3) ES2975215T3 (enExample)
WO (1) WO2013090770A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2583002T3 (es) 2007-04-09 2016-09-16 The Board Of Trustees Of The University Of Arkansas Proteínas de fusión de un dominio de enlazamiento a colágeno y hormona paratiroidea
WO2013120060A1 (en) 2012-02-09 2013-08-15 The Board Of Trustees Of The University Of Arkansas Delivery of therapeutic agents by a collagen binding protein
US9579273B2 (en) 2011-12-14 2017-02-28 The Kitasato Institute Delivery of therapeutic agents by a collagen binding protein
US11624060B2 (en) * 2017-02-10 2023-04-11 The Board Of Trustees Of The University Of Arkansas Collagen-binding agent compositions and methods of using the same
GB201706781D0 (en) 2017-04-28 2017-06-14 Univ Sheffield Parathyroid hormone fusion polypeptide
KR101964376B1 (ko) * 2017-09-29 2019-04-01 주식회사 나이벡 부갑상선호르몬(parathyroid hormone, PTH)에 골조직 선택성 펩타이드가 결합되어 있는 융합 펩타이드를 포함하는 약학 조성물 및 생체재료
JP7045166B2 (ja) * 2017-11-07 2022-03-31 株式会社ニッピ コラーゲン結合材、その製造方法、ドラッグデリバリーシステム、および担持体
JP2021516966A (ja) * 2018-03-09 2021-07-15 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 組織への生物学的薬物の送達
US20220363778A1 (en) * 2019-08-28 2022-11-17 The Research Foundation For The State University Of New York Targeted delivery of tumor matrix modifying enzymes
WO2022050176A1 (ja) * 2020-09-02 2022-03-10 コラジェン・ファーマ株式会社 ペプチドを含む組成物及びその用途
US12403179B2 (en) 2021-02-18 2025-09-02 The Board Of Trustees Of The University Of Arkansas Release of growth factors at wound healing stages
EP4543480A2 (en) * 2022-06-27 2025-04-30 Sustain Holdings, LLC Collagen peptide-based medicament compositions and uses thereof

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8516421D0 (en) 1985-06-28 1985-07-31 Biotechnology Interface Ltd Fibronectins
JP2950520B2 (ja) 1993-04-02 1999-09-20 アンティキャンサー インコーポレーテド 毛胞に有益な配合物を送達する方法
AU3819497A (en) 1996-07-31 1998-02-20 General Hospital Corporation, The Novel parathyroid hormone-related peptide analogs
US20100267012A1 (en) * 1997-11-04 2010-10-21 Bergeron Michel G Highly conserved genes and their use to generate probes and primers for detection of microorganisms
US6387663B1 (en) 1998-07-31 2002-05-14 University Of Southern California Targeting pharmaceutical agents to injured tissues
US7601685B2 (en) 1998-08-27 2009-10-13 Eidgenossische Technische Hochschule Zurich Growth factor modified protein matrices for tissue engineering
US20020102709A1 (en) 1999-02-19 2002-08-01 Tetsuya Ishikawa Collagen-binding physiologically active polypeptide
CN1347456A (zh) 1999-02-19 2002-05-01 泰尔茂株式会社 胶原结合生理活性多肽
US6908994B1 (en) 1999-05-10 2005-06-21 The Texas A&M University System Collagen-binding proteins from enterococcal bacteria
US6756480B2 (en) * 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US20050124537A1 (en) 2000-04-27 2005-06-09 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
EP1314780A4 (en) 2000-08-15 2004-07-28 Terumo Corp Collagen-binding hybrid polypeptides
JP2002058485A (ja) * 2000-08-16 2002-02-26 Terumo Corp コラーゲン結合性を有する骨形成促進融合蛋白質
CA2470419A1 (en) 2001-12-18 2003-06-26 Eidgenossisch Technische Hochschule Zurich Growth factor modified protein matrices for tissue engineering
CA2492295C (en) 2002-07-25 2014-01-28 The General Hospital Corporation Parathyroid hormone receptor activation and hematopoietic progenitor cell expansion
CA2516113A1 (en) 2003-02-13 2004-08-26 Synthes (U.S.A.) Injectable bone-replacement mixture
US20040220094A1 (en) 2003-05-01 2004-11-04 Skinner Keith K. Inverse agonist and agonist peptides that stimulate/inhibit hair growth
EP1680073B1 (en) 2003-10-21 2013-01-02 IGF Oncology, LLC Compounds and method for treating cancer
WO2005046798A1 (en) 2003-11-12 2005-05-26 Nps Allelix Corp. Treatment of bone loss utilizing full length parathyroid hormone
EP1557176A1 (en) 2004-01-26 2005-07-27 Ferring B.V. Treatment of bone metastases by means of PTH receptor agonists
US8030448B2 (en) * 2004-02-16 2011-10-04 Techno Network Shikoku Co., Ltd. Polypeptide having collagen-like structure
WO2005082941A1 (en) 2004-02-27 2005-09-09 The University Of Western Ontario Bone sialoprotein collagen-binding peptides
PL1759001T3 (pl) 2004-04-21 2011-09-30 Alexion Pharma Inc Koniugaty dostarczane do kości i sposób ich zastosowania do nakierowywania białek do kości
WO2006047214A2 (en) 2004-10-21 2006-05-04 Igf Oncology, Llc Toxins and radionuclides coupled to igf-1 receptor ligands for treatment of cancer
WO2006073711A2 (en) 2005-01-06 2006-07-13 Kuros Biosurgery Ag Use of a matrix comprising a contrast agent in soft tissues
ATE514712T1 (de) * 2005-12-26 2011-07-15 Yantai Zhenghai Bio Technology Co Ltd Aktivierte collagen-gerüstmaterialien und ihre speziellen kondensierten aktiven restorationsfaktoren
JP5645408B2 (ja) * 2006-11-16 2014-12-24 カイ ファーマシューティカルズ インコーポレーティッド 副甲状腺機能亢進症および高カルシウム血症性障害の治療のためのポリカチオン性カルシウムモジュレーターペプチド
EP1961765A1 (en) * 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
WO2008101406A1 (en) * 2007-02-14 2008-08-28 Yolare Dermaceuticals, Llc Modified mutant collagenase and it's use in fat melting and in scar reduction
WO2008123166A1 (en) * 2007-03-20 2008-10-16 Nsk-Warner K.K. Roller-type one-way clutch
ES2583002T3 (es) * 2007-04-09 2016-09-16 The Board Of Trustees Of The University Of Arkansas Proteínas de fusión de un dominio de enlazamiento a colágeno y hormona paratiroidea
US8486422B2 (en) * 2007-07-26 2013-07-16 Allergan, Inc. Methods of activating clostridial toxins
US20100159564A1 (en) * 2007-11-30 2010-06-24 Dwulet Francis E Protease resistant recombinant bacterial collagenases
JP5400336B2 (ja) 2008-08-04 2014-01-29 トヨタ紡織株式会社 表皮材の成形装置
US10545149B2 (en) 2008-10-06 2020-01-28 Morehouse School Of Medicine Detection of HIV-related proteins in urine
JP2010172247A (ja) 2009-01-29 2010-08-12 Kitasato Institute 積層型高密度培養人工組織の製造方法及び積層型高密度培養人工組織
WO2011060431A2 (en) * 2009-11-16 2011-05-19 University Of Maryland Baltimore Multivalent live vector vaccine against clostridium difficile-associated disease
WO2011142425A1 (ja) 2010-05-12 2011-11-17 国立大学法人香川大学 上皮層含有組織の再生材および再生評価方法
ES2385239B1 (es) * 2010-09-30 2013-06-19 Proteos Biotech S.L.U. Uso de colagenasa g recombinante, colagenasa h recombinante y pz-peptidasa recombinante para el tratamiento de enfermedades que cursan con alteraciones del colágeno.
ES2726530T3 (es) * 2011-03-16 2019-10-07 Univ Tohoku Sonda para analizar tejido biológico y método para utilizar la misma
WO2012157339A1 (ja) 2011-05-13 2012-11-22 学校法人北里研究所 成長因子アンカーリング型骨移植材料、成長因子アンカーリング型骨移植材料の製造方法、成長因子アンカーリング型骨移植材料製造用キット、および骨形成方法
WO2013120060A1 (en) * 2012-02-09 2013-08-15 The Board Of Trustees Of The University Of Arkansas Delivery of therapeutic agents by a collagen binding protein
US9579273B2 (en) * 2011-12-14 2017-02-28 The Kitasato Institute Delivery of therapeutic agents by a collagen binding protein
EP4772625A2 (en) * 2012-01-12 2026-07-08 Endo Biologics Limited Clostridium histolyticum enzyme
WO2013120030A1 (en) * 2012-02-08 2013-08-15 Shining Golden Yida Welding & Cutting Machinery Manufacture Ltd. Rotary vane air motor with improved vanes and other improvements
JP6403062B2 (ja) * 2012-12-21 2018-10-10 国立大学法人徳島大学 組織修復活性組成物及びその利用
SG11201602012RA (en) * 2013-09-25 2016-04-28 Pronutria Inc Compositions and formulations for maintaining and increasing muscle mass, strength, and performance and methods of production and use thereof
US9539363B2 (en) * 2014-04-24 2017-01-10 Warsaw Orthopedic, Inc. Collagen matrix
US20180140742A1 (en) * 2014-10-16 2018-05-24 School Juridical Person Kitasato Institute Graft material for nerve regeneration, method for producing graft material for nerve regeneration, and kit for producing graft material for nerve regeneration
EP3112474A1 (en) * 2015-06-29 2017-01-04 Evonik Degussa GmbH Method of detecting avian necrotic enteritis
US10513696B2 (en) * 2016-05-24 2019-12-24 Hamzeh Alipour Lucilia sericata collagenase
HUE063235T2 (hu) * 2016-09-29 2024-01-28 Ascendis Pharma Bone Diseases As Adagolási rendszer szabályozott leadású PTH vegyülethez
US11624060B2 (en) * 2017-02-10 2023-04-11 The Board Of Trustees Of The University Of Arkansas Collagen-binding agent compositions and methods of using the same
WO2019113123A1 (en) * 2017-12-04 2019-06-13 Precithera, Inc. TGF-ß RECEPTOR FUSION PROTEINS AND OTHER TGF-ß ANTAGONISTS FOR REDUCING TGF-ß SIGNALING
WO2019147735A1 (en) * 2018-01-23 2019-08-01 New York University Antibodies specific to delta 1 chain of t cell receptor
JP2021516966A (ja) * 2018-03-09 2021-07-15 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 組織への生物学的薬物の送達
EP3836923B1 (en) * 2018-08-14 2024-10-16 OssiFi Therapeutics LLC Pyrrolo - dipyridine compounds for the treatment of bone loss

Also Published As

Publication number Publication date
EP2790717B1 (en) 2018-05-30
US11279922B2 (en) 2022-03-22
US20140377215A1 (en) 2014-12-25
US9579273B2 (en) 2017-02-28
EP3808365C0 (en) 2024-01-31
JP2022023162A (ja) 2022-02-07
ES2695161T3 (es) 2019-01-02
US11001820B2 (en) 2021-05-11
JP6366507B2 (ja) 2018-08-01
DK2790717T3 (da) 2018-07-30
CA3113972A1 (en) 2013-06-20
EP2790717A4 (en) 2016-03-09
EP3808365B1 (en) 2024-01-31
EP3391899B1 (en) 2020-07-15
EP2790717A2 (en) 2014-10-22
WO2013090770A3 (en) 2014-12-31
JP2015513312A (ja) 2015-05-07
US20190249163A1 (en) 2019-08-15
JP2020073554A (ja) 2020-05-14
ES2975215T3 (es) 2024-07-04
EP4397755A3 (en) 2025-01-01
US20170204390A1 (en) 2017-07-20
CA2859412A1 (en) 2013-06-20
EP4397755A2 (en) 2024-07-10
WO2013090770A2 (en) 2013-06-20
JP7327765B2 (ja) 2023-08-16
JP2018104461A (ja) 2018-07-05
DK3391899T3 (da) 2020-08-24
CA3113972C (en) 2023-08-01
EP3808365A1 (en) 2021-04-21
JP2023153154A (ja) 2023-10-17
EP3391899A1 (en) 2018-10-24
JP6697019B2 (ja) 2020-05-20
ES2816009T3 (es) 2021-03-31

Similar Documents

Publication Publication Date Title
US11279922B2 (en) Delivery of therapeutic agents by a collagen binding protein
US10213488B2 (en) Delivery of therapeutic agents by a collagen binding protein
JP2003505075A5 (enExample)
WO2002096356A2 (en) HIGH AFFINITY LIGAND FOR p75 NEUROTROPHIN RECEPTOR
CA2484994C (en) Peptide antagonists of tgf-beta family members and therapeutic uses thereof
JP7682503B2 (ja) コラーゲン結合薬剤組成物およびその使用方法
US7772204B1 (en) Perlecan and growth factor for wound and cutaneous injury healing
JP2017513856A (ja) 毛成長抑制のためのオステオポンチン誘導体を含む組成物
CZ283601B6 (cs) Inzulinu podobný růstový faktor vázající protein odvozený z lidské kosti
WO2024077335A1 (en) Factor ix variant polypeptides for administration to soft tissue

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20171204

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241206

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241206